Press Release: Kymriah(R) (tisagenlecleucel), -3-

lymphoma: results from the international SCHOLAR-1 study", Blood.

https://www.ncbi.nlm.nih.gov/pubmed/28774879 2017 Oct

19;130(16):1800-1808. Available on

https://www.ncbi.nlm.nih.gov/pubmed/28774879. Accessed April 2018.

# # #

Novartis Media Relations

Central media line: +41 61 324 2200

E-mail: media.relations@novartis.com

Eric Althoff Fiona Phillips

Novartis Global Media Relations Novartis Oncology Communications

+41 61 324 7999 (direct) +1 862-778-7705 (direct)

+41 79 593 4202 (mobile) +1 862-217-9396 (mobile)

eric.althoff@novartis.com fiona.phillips@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2187989/846991.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;

http://www.novartis.com

(END) Dow Jones Newswires

May 01, 2018 16:26 ET (20:26 GMT)